Novo Nordisk's Pipeline Puzzle Deepens as Paediatric Win Fails to Distract Investors
Published on 09/08/2026 at 12:33 | Editorial boerse-global.de
The Danish pharmaceutical giant delivered a study in contrasts this week, unveiling encouraging data in childhood obesity while simultaneously pulling the plug on two more late-stage cardiovascular trials. For shareholders trying to read the tea leaves, the mixed messaging could hardly be more confusing.
A Cardiology Strategy Unravels
Novo Nordisk has terminated the HERMES and ATHENA Phase 3 trials investigating Ziltivekimab, an IL-6 inhibitor being developed for heart failure. The company cited a low probability of success following a committee review — clinical-trial speak for "the data simply weren't pointing where we hoped."
This marks the second stumble for the programme within weeks. The ZEUS study had already failed back in July, leaving only the ARTEMIS trial in post-heart-attack patients still running, with results expected in the first half of 2027.
The setback carries particular sting given the acquisition history. Ziltivekimab arrived via the $725 million takeover of Corvidia back in 2020 — a bet that was supposed to prove Novo Nordisk could build a meaningful third pillar beyond its metabolic franchise. Two failed studies in quick succession suggest that ambition is now on life support.
Notably, the broader industry context offers some cover. Novartis simultaneously disclosed that its cardiovascular candidate Pelacarsen had missed its primary endpoint in an advanced study — a reminder that cardiology drug development is proving treacherous across the sector, not just in Bagsværd.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Paediatric Milestone Worth Celebrating
The same Monday brought genuinely positive news from the STEP-Young trial, which tested semaglutide in children aged six to under twelve with obesity. After 68 weeks, 40.4 percent of treated children were no longer classified as obese, against zero percent in the placebo group.
The baseline severity makes the result all the more striking: over 85 percent of participants entered the study with class II or III obesity. This represents the first dataset of its kind in such a young demographic, and rival Eli Lilly has yet to produce comparable evidence.
The commercial timeline, however, demands patience. Paediatric regulatory pathways move slowly, and the revenue contribution is unlikely to materialise in the near term. The scientific validation of the semaglutide platform is real — the earnings impact is a story for another year.
Oral Wegovy and the China Question
Sandwiched between these developments sits the rollout of the oral Wegovy tablet in Germany, which began in early September as the first EU market to receive the product. The tablet represents a potential long-term improvement in treatment adherence, though it does little to address the structural question hanging over the company.
The regulatory picture in China remains equally uncertain. The Chinese drug authority accepted the oral Wegovy application in August, but Novo Nordisk has offered no timeline for approval — an opportunity acknowledged, but one whose contours remain frustratingly vague.
Guidance and the September 21 Reckoning
August brought a revision to the company's 2026 outlook, with revenue and operating profit now expected to range from zero to minus six percent at constant exchange rates — a meaningful improvement on the previous guidance of minus twelve to minus four percent.
Yet the upgrade came wrapped in caution. Management explicitly flagged ongoing uncertainty ahead of the capital markets day scheduled for September 21, a date that investors increasingly view as the moment of truth for the company's diversification narrative.
Deutsche Bank had already moved to a Sell rating in late August, trimming its price target from DKK 290 to DKK 265, citing a mixed second quarter and cautious guidance. That call now looks prescient rather than premature.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Reading the Tape
The share price tells a story of tempered expectations. At €39.73, the stock sits roughly 28 percent below its 52-week high of €54.86 reached in late January. Yet the recovery from the March trough of €30.25 — a 31 percent rebound — suggests the market hasn't abandoned the name entirely.
The relative strength index of 46.8 points to a stock that is neither overbought nor oversold, with the recent news flow already digested rather than triggering fresh panic. That equilibrium feels appropriate: the Ziltivekimab setback, while damaging to the diversification thesis, never formed the core of the investment case.
More concerning for the medium term are early signs of demand softening in the weight-loss franchise. Brazilian import data for polypeptide hormone-based medications — a proxy for GLP-1 demand — fell 22 percent in August compared with July, according to Citi. The signal is regional, but it hints at the pricing elasticity and competitive pressures from generics and biosimilars that lie ahead.
The Verdict
Novo Nordisk finds itself in an uncomfortable middle ground: scientifically formidable, commercially showing its first hairline cracks, and strategically yet to prove it can thrive beyond obesity and diabetes. The paediatric data reinforce the durability of the semaglutide platform, while the cardiology failures underscore how difficult diversification has become.
Whether the current discount to January's highs is justified or excessive will depend on whether the demand softness visible in Brazil spreads to other markets. The September 21 capital markets day offers management its best chance to address these concerns head-on. Until then, the weight of evidence suggests caution rather than conviction — in either direction.
Ad
Novo Nordisk Stock: New Analysis - 8 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
